Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

▎药明康德优于现有疗法！Moderna流感mRNA疫苗3期结果积极Moderna今日公布其季节性流感mRNA疫苗mRNA-1010在3期临床研究（P304）积极进展。该研究在50岁及以上的成人群体中评估了mRNA-1010相较于获批标准剂量季节性流感 ...

Moderna 的季节性流感 mRNA 疫苗 mRNA-1010 在 III 期试验中展现出显著优势 —— 在 50 岁及以上人群中，其预防流感的效果比现有标准剂量疫苗高出 26.6%。这项覆盖 11 个国家、超 4 万名受试者的研究显示，65 岁以上老年人群的保护效力提升更为明显，达 27.4%。细分病毒株数据进一步验证其优势：对 A/H1N1 株保护效力提高 29.6%，A/H3N2 株提高 ...

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

近年来，流感疫苗的研发一直是公众和医学界关注的热点。随着Moderna公司最新的季节性流感mRNA疫苗mRNA-1010在III期临床试验中取得显著成果，流感疫苗的未来似乎迎来了新的曙光。这项覆盖11个国家、超过4万名受试者的研究结果显示，mRNA-1010在50岁及以上人群中的预防效果比现有的标准剂量疫苗高出26.6%。对于65岁以上的老年人群体，其保护效力更是提升至27.4%。这一数据不仅让人 ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

智通财经APP获悉，周四，医药板块涨跌不一，截至发稿，礼来 (LLY.US)跌0.51%，诺和诺德 (NVO.US)跌超1%；Moderna (MRNA.US)涨0.86%，联合健康 (UNH.US)涨0.9%，辉瑞 (PFE.US)涨0.59%。消息面上，美国卫生部长肯尼迪上周批准了美国疾病控制与预防中心 (CDC)关于呼吸道合胞病毒 ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Moderna美股盘前涨超6%。 一周牛熊股丨15股周涨超40%，最牛股周涨超95% 一周牛熊股丨15股周涨超40%，最牛股周涨超95% 一周牛熊股 ...